Table 1.

Patient characteristics stratified by HIV status and RDW category. P-value <0.001 for all comparisons between RDW categories.

	HIV+		HIV−
	Low RDW	High RDW	Low RDW	High RDW
Number of patients	30,150	16,570	7,969,250	1,617,900
Age (years)
20–24	800 (3%)	270 (2%)	598,560 (8%)	78,630 (5%)
25–29	2,140 (7%)	730 (4%)	802,550 (10%)	118,250 (7%)
30–34	2,570 (9%)	1,050 (6%)	873,500 (11%)	141,010 (9%)
35–39	3,100 (10%)	1500 (9%)	864,190 (11%)	153,850 (10%)
40–44	3,390 (11%)	1,990 (12%)	810,060 (10%)	159,670 (10%)
45–49	4,760 (16%)	2,830 (17%)	865,350 (11%)	184,790 (11%)
50–54	5,720 (19%)	3,200 (19%)	925,350 (12%)	213,800 (13%)
55–59	4,340 (14%)	2,740 (17%)	984,120 (12%)	242,890 (15%)
60–64	2,860 (9%)	1,930 (12%)	910,420 (11%)	255,090 (16%)
Gender
Male	22,320 (74%)	10,110 (61%)	3,419,430 (43%)	496,580 (31%)
Female	7,830 (26%)	6,450 (39%)	4,547,640 (57%)	1,120,910 (69%)
Race
African American	12,740 (42%)	10,200 (62%)	911,050 (11%)	427,450 (26%)
Caucasian	14,450 (48%)	5,090 (31%)	5,859,390 (74%)	966,950 (60%)
Insurance
Private	13,670 (45%)	5,750 (35%)	4,516,050 (57%)	811,620 (50%)
Medicaid	7,420 (25%)	5,010 (30%)	910,970 (11%)	279,160 (17%)
Medicare	5,750 (19%)	4,130 (25%)	503,640 (6%)	199,900 (12%)
Antiretroviral therapy
Any ART	15,990 (53%)	8,280 (50%)	N/A	N/A
Protease Inhibitor	8,600 (29%)	5,530 (33%)	N/A	N/A
Integrase Inhibitor	2,460 (8%)	1,550 (9%)	N/A	N/A
Reverse Transcriptase Inhibitor	15,390 (51%)	7,900 (48%)	N/A	N/A
Tenofovir	12,600 (42%)	5,700 (34%)	N/A	N/A
Thymidine analogue (Stavudine/Zidovudine)	2,600 (9%)	2,080 (13%)	N/A	N/A
Risk factors
Diabetes	4,030 (13%)	3,630 (22%)	684,700 (9%)	288,620 (18%)
Hypertension	10,740 (36%)	7,990 (48%)	1,853,780 (23%)	603,720 (37%)
Dyslipidemia	9,180 (30%)	4,540 (27%)	1,747,490 (22%)	413,160 (26%)
Smoking	11,970 (40%)	7,380 (45%)	1,383,800 (17%)	361,270 (22%)